article thumbnail

Former AbbVie executive Severino joins Flagship-backed startup as CEO

Bio Pharma Dive

Severino left the pharma company in April after eight years as its chief scientist and then president. He'll lead Tessera Therapeutics, a well-funded genetic medicine startup.

article thumbnail

Italfarmaco’s Duvyzat Wins FDA Approval as First Nonsteroidal Treatment for All Genetic Variants of DMD

XTalks

Duvyzat, a histone deacetylase (HDAC) inhibitor that works to reduce inflammation and muscle loss, is the first nonsteroidal drug approved to treat patients with all genetic variants of DMD. Progressive muscle weakness in the disease is caused by genetic mutations in the dystrophin gene that lead to a lack of functional dystrophin protein.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Can genetic data be a magic bullet for drug R&D?

pharmaphorum

Drug development has long been an issue for the pharma industry, due to the expense and the high failure rate of potential treatments. Ben Hargreaves finds that the vast amount of genetic data that exists today could help provide a faster, more targeted way of developing new drug candidates.

article thumbnail

How Pharma Companies Can – And Should – Improve Social Determinants of Health

Intouch Solutions

SDOH can drive as much as 80% of health outcomes 3,4 A person’s zip code, not their genetic code, is the stronger predictor of their health! Companies can also support pre-existing SDOH research initiatives. 1 Why are SDOH important? Studies should include as detailed SDOH data as possible.

article thumbnail

Ipsen plans sale of consumer health business for €350m

pharmaphorum

Ipsen has started exclusive negotiations that could see its global consumer health business sold to fellow French pharma company Mayoly Spindler later this year. billion takeover of Clementia Pharma in 2019. billion takeover of Clementia Pharma in 2019. billion of its revenues last year.

Sales 92
article thumbnail

Sohonos (Palovarotene) Sets Milestone as First Drug for Ultra-Rare Bone Disease

XTalks

“For the first time, doctors have an approved medicine available to them, shown to reduce the formation of new, abnormal bone growth, known as heterotopic ossification (HO), which causes debilitating mobility challenges and has a devastating impact on the lives of people with FOP.”

Drugs 98
article thumbnail

Takeda grows in gene therapies again with $2bn Code Bio deal

pharmaphorum

The Japanese drugmaker will get access to Code Bio’s 3DNA non-viral genetic medicine delivery platform, initially for a liver-directed programme, and is also interested in deploying the technology for central nervous system disorders.